Applied Genetic Technologies Corporation
http://www.agtc.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Applied Genetic Technologies Corporation
AGTC Moves Past Biogen With Ophthalmic Gene Therapy
AGTC hopes to gain the first approval in X-linked retinitis pigmentosa for its gene therapy AGTC-501, now in a Phase II/III study. It also is advancing development in achromatopsia, another unmet medical need.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
CureVac’s German Owner Rejects US Coronavirus Vaccine Grab
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics